[go: up one dir, main page]

BR0207827A - Método de preparação de uma micropartìcula homogênea que compreende um inibidor de h+/k+-atpase ácido lábil, micropartìcula, composição farmacêutica, método para prevenir ou tratar uma doença relacionada com o ácido gástrico em um mamìfero, e, uso de uma micropartìcula - Google Patents

Método de preparação de uma micropartìcula homogênea que compreende um inibidor de h+/k+-atpase ácido lábil, micropartìcula, composição farmacêutica, método para prevenir ou tratar uma doença relacionada com o ácido gástrico em um mamìfero, e, uso de uma micropartìcula

Info

Publication number
BR0207827A
BR0207827A BR0207827-9A BR0207827A BR0207827A BR 0207827 A BR0207827 A BR 0207827A BR 0207827 A BR0207827 A BR 0207827A BR 0207827 A BR0207827 A BR 0207827A
Authority
BR
Brazil
Prior art keywords
microparticle
sup
mammal
treating
preparing
Prior art date
Application number
BR0207827-9A
Other languages
English (en)
Inventor
Haakan Glad
Malin Soederbom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0207827A publication Critical patent/BR0207827A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

"MéTODO DE PREPARAçãO DE UMA MICROPARTìCULA HOMOGêNEA QUE COMPREENDE UM INIBIDOR DE H^ +^/K^ +^-ATPASE áCIDO LáBIL, MICROPARTìCULA, COMPOSIçãO FARMACêUTICA, MéTODO PARA PREVENIR OU TRATAR UMA DOENçA RELACIONADA COM O áCIDO GáSTRICO EM UM MAMìFERO, E, USO DE UMA MICROPARTìCULA". Método para a preparação de micropartículas homogêneas contendo um inibidor de H^ +^,K^ +^-ATP-ASE usando uma técnica de granulação de leito fluido. As micropartículas que possuem uma distribuição de tamanho desejada são selecionadas. Pelo menos 80% da micropartículas com base em seu conteúdo de peso seco é o inibidor de H^ +^/K^ +^-ATPase ácido lábil.
BR0207827-9A 2001-03-09 2002-03-06 Método de preparação de uma micropartìcula homogênea que compreende um inibidor de h+/k+-atpase ácido lábil, micropartìcula, composição farmacêutica, método para prevenir ou tratar uma doença relacionada com o ácido gástrico em um mamìfero, e, uso de uma micropartìcula BR0207827A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100822A SE0100822D0 (sv) 2001-03-09 2001-03-09 Method II to obtain microparticles
PCT/SE2002/000400 WO2002072071A1 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor

Publications (1)

Publication Number Publication Date
BR0207827A true BR0207827A (pt) 2004-03-02

Family

ID=20283293

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207827-9A BR0207827A (pt) 2001-03-09 2002-03-06 Método de preparação de uma micropartìcula homogênea que compreende um inibidor de h+/k+-atpase ácido lábil, micropartìcula, composição farmacêutica, método para prevenir ou tratar uma doença relacionada com o ácido gástrico em um mamìfero, e, uso de uma micropartìcula

Country Status (22)

Country Link
US (2) US20040101565A1 (pt)
EP (1) EP1370243B1 (pt)
JP (1) JP2004522796A (pt)
KR (1) KR20030081506A (pt)
CN (1) CN1507343A (pt)
AT (1) ATE400253T1 (pt)
AU (1) AU2002235101B8 (pt)
BR (1) BR0207827A (pt)
CA (1) CA2440163A1 (pt)
DE (1) DE60227488D1 (pt)
DK (1) DK1370243T3 (pt)
ES (1) ES2307722T3 (pt)
HK (1) HK1059896A1 (pt)
IL (1) IL157467A0 (pt)
MX (1) MXPA03007887A (pt)
NO (1) NO20033966L (pt)
NZ (1) NZ527997A (pt)
PT (1) PT1370243E (pt)
SE (1) SE0100822D0 (pt)
SI (1) SI1370243T1 (pt)
WO (1) WO2002072071A1 (pt)
ZA (1) ZA200306614B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US8449911B2 (en) 2003-03-12 2013-05-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2007095376A2 (en) * 2006-02-15 2007-08-23 Kennametal Inc. Method and apparatus for coating particulates utilizing physical vapor deposition
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US20090087569A1 (en) * 2007-09-27 2009-04-02 Fenchem Enterprises Ltd. Methods for Preparing Highly Stable Hyaluronic Acid
IT1401284B1 (it) * 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20230058473A1 (en) * 2020-01-27 2023-02-23 Towa Pharmaceutical Co., Ltd. Esomeprazole oral preparation and method for producing the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0163836B1 (de) * 1984-04-07 1988-10-12 Bayer Ag Verfahren und Vorrichtung zur Herstellung von Granulaten
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE3909455A1 (de) * 1989-03-22 1990-09-27 Hoechst Ag Verfahren zur herstellung von wasserdispergierbaren granulaten
DK1078628T3 (da) * 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
DE19613395A1 (de) * 1996-04-03 1997-10-09 Basf Ag Granulate hygroskopischer, wasserlöslicher Produkte
DE19733094A1 (de) * 1997-07-31 1999-02-04 Merck Patent Gmbh Formulierung auf der Basis von Ascorbinsäure mit verbesserter Farbstabilität
DE59813833D1 (de) * 1997-10-15 2007-01-11 Merck Patent Gmbh Herstellung eines direkt verpressbaren tablettierhilfsstoffes
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ES2216351T3 (es) * 1997-12-08 2004-10-16 Altana Pharma Ag Nueva forma de supositorio que comprende un compuesto activo labil o acidos.
SE9903236D0 (sv) * 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles

Also Published As

Publication number Publication date
AU2002235101B8 (en) 2006-08-31
IL157467A0 (en) 2004-03-28
WO2002072071A1 (en) 2002-09-19
US20080175917A1 (en) 2008-07-24
EP1370243A1 (en) 2003-12-17
US20040101565A1 (en) 2004-05-27
NO20033966L (no) 2003-11-03
NZ527997A (en) 2005-02-25
ES2307722T3 (es) 2008-12-01
JP2004522796A (ja) 2004-07-29
AU2002235101B2 (en) 2006-07-13
PT1370243E (pt) 2008-09-16
ZA200306614B (en) 2004-11-25
ATE400253T1 (de) 2008-07-15
HK1059896A1 (en) 2004-07-23
KR20030081506A (ko) 2003-10-17
SE0100822D0 (sv) 2001-03-09
CA2440163A1 (en) 2002-09-19
CN1507343A (zh) 2004-06-23
MXPA03007887A (es) 2003-12-04
DE60227488D1 (de) 2008-08-21
DK1370243T3 (da) 2008-10-13
EP1370243B1 (en) 2008-07-09
SI1370243T1 (sl) 2008-12-31
NO20033966D0 (no) 2003-09-08

Similar Documents

Publication Publication Date Title
BR0207827A (pt) Método de preparação de uma micropartìcula homogênea que compreende um inibidor de h+/k+-atpase ácido lábil, micropartìcula, composição farmacêutica, método para prevenir ou tratar uma doença relacionada com o ácido gástrico em um mamìfero, e, uso de uma micropartìcula
NO870558L (no) Fremgangsmaate for fremstilling av et langsomt frigivende farmasoeytisk preparat.
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0206985A (pt) Anticorpos modificados e métodos de uso
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
SI1887016T1 (sl) Fragmenti človeškega horijevega gonadotropina (hcg) kot imunoregulator
BR0312464A (pt) Inibidores de tirosina quinases
BR0110420A (pt) Agonistas muscarìnicos
PT100514A (pt) 3-aminoquinuclidinas substituidas e composicoes farmaceuticas que qs contem
ATE350013T1 (de) Nanopartikelzusammensetzungen enthaltend insulin
BR0007487A (pt) Difenil-uréias substituìdas com w-carbóxi-arilas como inibidores de raf cinase
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
BRPI0015061B8 (pt) comprimido revestido tendo alta dosagem de cloridrato de sevelamer
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
BR9811099A (pt) Inibidores de urocinase
BR0215175A (pt) Métodos para a granulação úmida de azitromicina
BR0207919A (pt) Método para a preparação de uma micropartìcula homogênea de metoprolol, micropartìcula, composição farmacêutica, método para prevenir ou tratar um distúrbio cardiovascular em um mamìfero, e, uso de uma micropartìcula
ATE205881T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
CA2408541A1 (en) Treating eczema and/or psoriasis
BR9915390A (pt) Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas
BR0314783A (pt) Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias
CO5150233A1 (es) Formulacion de liberacion controlada para administrar un inhibidor de pde4
PT1186292E (pt) Preparados solidos com estrutura multinuclear
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.